Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONTY $3.01 0.5000 +19.92%
CBMG $35.64 4.5100 +14.49%
BLRX $2.02 0.1700 +9.19%
XBIT $20.59 1.5400 +8.08%
INO $8.83 0.5700 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CALA $11.00 -1.0200 -8.49%
TKAI $10.95 -0.9100 -7.67%
CLSN $2.63 -0.1701 -6.08%
CVM $0.75 -0.0400 -5.06%
BDSI $8.10 -0.3900 -4.59%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Combined Radiation and Hormonal Therapy Improves Survival in Node-positive Prostate Cancer

(Mass General) May 11, 2015 - A new study finds that men with prostate cancer that has spread to nearby lymph nodes, who have a significant risk of dying from the disease, can benefit from the addition of radiation therapy to treatments that block the effects of testosterone.
read press release 

Lilly Joins with German Biotech Firm in Cancer-fighting Venture

(Indianapolis Star) May 11, 2015 - Eli Lilly and Co. will pay $30 million to tap a German biotech firm's expertise in using the body's own immune system to attack cancer cells.
read article 

Merck KGaA, Threshold Win Fast Track for Pancreatic Cancer Drug

(Fox May 12, 2015 - Germany's Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.S. Food and Drug Administration.
read article 

Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer

(CNN Money) May 12, 2015 - Threshold Pharmaceuticals, Inc. today announced that the FDA has granted Fast Track designation to the Company's partner Merck KGaA, Darmstadt, Germany, for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.
read article 

NewLink's Pancreatic Cancer Vaccine on Long Road to Study Failure

(TheStreet) May 12, 2015 - The odds are now high that NewLink's HyperAcute pancreas vaccine will prove to be a failure once a final survival analysis is conducted later this year or in early 2016.
read article 

A New Way to Use Old Tools Against Ovarian Cancer

(Wall Street Journal) May 11, 2015 - The approach is based on being smarter about using the longtime mainstay treatments for ovarian cancer: surgery and chemotherapy.
read article (paid subscription required) 

ASCO Releases Updated, Expanded Set of Survivorship Care Planning Templates

(ASCO in Action) May 11, 2015 - The American Society of Clinical Oncology (ASCO) today issued an updated and expanded set of treatment and survivorship care plan templates for oncology care professionals and patients with cancer. The templates serve to enhance ASCO's existing suite of tools to help providers and patients fully plan a course of cancer treatment from diagnosis to survivorship care.
read article 

Scottish Cost Regulators OK NHS Use of 7 New Drugs

(PharmaTimes [UK]) May 11, 2015 - The Scottish Medicines Consortium has approved seven new medicines for use on NHS Scotland, including the first biologic treatment for ulcerative colitis, which affects around 12,400 people across the country
read article 

W.H.O. Urges More Care in Naming Diseases

(New York Times) May 8, 2015 - The World Health Organization issued recommendations for naming infectious diseases, concerned about stigmas of names like swine flu and monkeypox.
read article 

The Problem With Obama’s Plan to Pay Doctors Based on Performance

(Bloomberg) May 8, 2015 - As Medicare prepares to begin rating doctors on a scale from 0 to 100, there’s confusion about how to define success.
read article 

Hunt for AIDS Cure Accelerates as GSK and US Experts Link Up

(CNBC/Reuters) May 11, 2015 - Britain's GlaxoSmithKline is to collaborate with U.S. scientists in developing a cure for AIDS.
read article 

Vertex’s Cystic-Fibrosis Drug Faces Big Test

(Wall Street Journal) May 9, 2015 - An FDA advisory committee on Tuesday will consider whether to recommend approval of biotech Vertex’s experimental cystic-fibrosis drug, Orkambi.
read article (paid subscription required) 

Why the Newest Sunscreens Still Haven’t Hit the U.S. Market

(Washington Post/To Your Health) May 11, 2015 - The FDA is being urged to speed up its review of new and potentially better sunscreen ingredients.
read article (free registration required) 

Eduardo M. Sotomayor, M.D., Renowned Cancer Researcher and Physician-Scientist, to Lead GW Cancer Center

(GW School of Medicine) May 11, 2015 — The George Washington University (GW) School of Medicine and Health Sciences (SMHS), the GW University Hospital, and the GW Medical Faculty Associates are pleased to announce the appointment of Eduardo M. Sotomayor, M.D., who will serve as the inaugural director of the GW Cancer Center.
read press release 

The Project Data Sphere® initiative Achieves 1st Year Milestones

(Bloomberg) May 11, 2015 - Cancer community broadly shares, integrates, and analyzes clinical trial data within a single research platform to advance innovation and improve lives.
read article 

ASH Contributes to the NHLBI's Strategic Visioning Process

(ASH) May 8, 2015 - The National Heart, Lung, and Blood Institute (NHLBI) is conducting a strategic visioning exercise that aims to identify compelling questions and critical challenges in scientific knowledge, healthcare quality, and workforce issues that should be addressed within the next decade.
read article 

NIH Funding in Spotlight During Hill Advocacy

(ASCO in Action) May 8, 2015 - On May 7, volunteers from the American Association for Cancer Research, the Association of American Cancer Institutes, and the American Society of Clinical Oncology were on Capitol Hill to meet with Senators and staff to discuss the urgent need for increased financial support for the National Institutes for Health (NIH).
read article 

ASCO Submits Testimony for FY2016 Appropriations: Progress Against Cancer Threatened Without Increased Federal Research Funding

(ASCO in Action) May 5, 2015 - ASCO has submitted testimony to the U.S. House of Representatives Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies pressing for increased funding for the National Cancer Institute (NCI) and the National Institutes of Health (NIH) for the 2016 fiscal year (FY2016).
read article 

Varian Medical Systems Launches OncoPeer, a Cloud-Based Resource for Sharing Clinical Information and Experience

(Virtual-Strategy Magazine) May 11, 2015 - Varian Medical Systems today announced the launch of OncoPeer™, a cloud-based interactive resource for oncology professionals intended to help improve the efficiency, quality, and consistency of care in cancer clinics.
read article 

IsoRay's Cesium-131 Cancer Treatment Takes Center Stage at Weill Cornell's International Symposium "Advances in Brachytherapy”

(Yahoo! Finance) May 11, 2015 - Successful Cesium-131 cancer treatment results, methods and patient selection criteria were presented in a peer to peer forum of leading medical professionals.
read article 

Nanobiotix Expands Soft Tissue Sarcoma Pivotal Clinical Trial Across Europe and Beyond, According to Plan

(Bloomberg) May 11, 2015 – NANOBIOTIX announces the expansion of the pivotal phase II/III trial for NBTXR3 in Soft Tissue Sarcoma (STS). This trial is the final step before registration (CE mark).
read article 

St. Gallen International Breast Cancer Guidelines for the Third Time Distinguish Oncotype DX(R) as the Only Multi-Gene Test Validated to Predict Chemotherapy Benefit

(Morningstar) May 11, 2015 - Genomic Health today announced that the 14th St. Gallen International Breast Cancer Conference Expert Panel, for the third time, recognized the Oncotype DX® breast cancer test for its ability to provide not only prognostic but also predictive information regarding the likelihood of chemotherapy benefit for patients with early-stage, estrogen receptor-positive, invasive breast cancer.
read article 

What Do Cancer Centers Think Patients Are Looking For?

(Forbes) May 11, 2015 - If you were a cancer center trying to get patients to come to receive care at your facility, what message would you send them? In other words, what would you as a cancer center director think people would value in choosing a place to receive cancer care?
read article 

Celgene CEO Says Early-Stage Partnerships Begin to Show Promise

(Bloomberg) May 8, 2015 - Celgene Corp. Chief Executive Officer Robert J. Hugin said his partnerships with companies in the early stages of drug development are bearing fruit, yielding more than half of eight new compounds the company aims to put into human testing over the next 18 months.
read article 

Heat Biologics Announces Initiation of Phase 1b Trial of Viagenpumatucel-L (HS-110) in Non-Small Cell Lung Cancer (NSCLC)

(MarketWatch) May 11, 2015 - Heat Biologics, Inc. announced today that it has enrolled the first patient in a new Phase 1b trial of Viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer ("NSCLC”).
read article